These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 23155322)

  • 21. Efficacy of PEG-interferon based treatment in patients with hepatitis C refractory to previous conventional interferon-based treatment.
    Shaikh S; Devrajani BR; Kalhoro M
    J Coll Physicians Surg Pak; 2012 Oct; 22(10):635-9. PubMed ID: 23058146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-α2a treatment.
    Mederacke I; Yurdaydin C; Dalekos GN; Bremer B; Erhardt A; Cakaloglu Y; Yalcin K; Gurel S; Zeuzem S; Zachou K; Bozkaya H; Dienes HP; Manns MP; Wedemeyer H;
    Antivir Ther; 2012; 17(2):305-12. PubMed ID: 22293066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: A meta-analysis.
    Abdrakhman A; Ashimkhanova A; Almawi WY
    Antiviral Res; 2021 Jan; 185():104995. PubMed ID: 33321155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical presentation of hepatitis D in Pakistani children.
    Abbas Z; Soomro GB; Hassan SM; Luck NH
    Eur J Gastroenterol Hepatol; 2014 Oct; 26(10):1098-103. PubMed ID: 25089545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection: longitudinal analysis of a German cohort.
    Bockmann JH; Grube M; Hamed V; von Felden J; Landahl J; Wehmeyer M; Giersch K; Hall MT; Murray JM; Dandri M; Lüth S; Lohse AW; Lütgehetmann M; Schulze Zur Wiesch J
    BMC Gastroenterol; 2020 Jan; 20(1):24. PubMed ID: 32000689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resolution of chronic hepatitis Delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine.
    Mansour W; Ducancelle A; Le Gal F; Le Guillou-Guillemette H; Abgueguen P; Pivert A; Calès P; Gordien E; Lunel F
    J Clin Virol; 2010 Jan; 47(1):97-9. PubMed ID: 19914127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis D virus: an update.
    Pascarella S; Negro F
    Liver Int; 2011 Jan; 31(1):7-21. PubMed ID: 20880077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of twelve weeks of treatment with ezetimibe on HDV RNA level in patients with chronic hepatitis D.
    Abbas Z; Saad M; Asim M; Abbas M; Samejo SA
    Turk J Gastroenterol; 2020 Feb; 31(2):136-141. PubMed ID: 32141822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b.
    Erhardt A; Gerlich W; Starke C; Wend U; Donner A; Sagir A; Heintges T; Häussinger D
    Liver Int; 2006 Sep; 26(7):805-10. PubMed ID: 16911462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Entecavir treatment of chronic hepatitis D.
    Kabaçam G; Onder FO; Yakut M; Seven G; Karatayli SC; Karatayli E; Savas B; Idilman R; Bozdayi AM; Yurdaydin C
    Clin Infect Dis; 2012 Sep; 55(5):645-50. PubMed ID: 22573857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study.
    Yurdaydin C; Keskin O; Kalkan Ç; Karakaya F; Çalişkan A; Karatayli E; Karatayli S; Bozdayi AM; Koh C; Heller T; Idilman R; Glenn JS
    Hepatology; 2018 Apr; 67(4):1224-1236. PubMed ID: 29152762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis.
    Kabaçam G; Dalekos GN; Çakaloğlu Y; Zachou K; Bock T; Erhardt A; Zeuzem S; Tabak F; Yalçin K; Bozdayi AM; Dienes HP; Bozkaya H; Manns M; Wedemeyer H; Yurdaydin C
    Turk J Gastroenterol; 2012; 23(5):560-8. PubMed ID: 23161302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of delta hepatitis.
    Gunsar F
    Expert Rev Anti Infect Ther; 2013 May; 11(5):489-98. PubMed ID: 23627855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Durable virological response and functional cure of chronic hepatitis D after long-term peginterferon therapy.
    Hercun J; Kim GE; Da BL; Rotman Y; Kleiner DE; Chang R; Glenn JS; Hoofnagle JH; Koh C; Heller T
    Aliment Pharmacol Ther; 2021 Jul; 54(2):176-182. PubMed ID: 34048594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of hepatitis delta virus genotype 3 infection with peg-interferon and entecavir.
    Borzacov LM; de Figueiredo Nicolete LD; Souza LF; Dos Santos AO; Vieira DS; Salcedo JM
    Int J Infect Dis; 2016 May; 46():82-8. PubMed ID: 27005283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
    Perrakis A; Yedibela S; Schuhmann S; Croner R; Schellerer V; Demir R; Hohenberger W; Müller V
    Transplant Proc; 2011 Dec; 43(10):3824-8. PubMed ID: 22172854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of polymorphisms in interferon λ 3 (interleukin 28B) on sustained virologic response to therapy in patients with chronic hepatitis D virus infection.
    Yilmaz E; Baran B; Soyer OM; Onel M; Onel D; Ormeci AC; Gokturk S; Evirgen S; Akyuz F; Demir K; Besisik F; Kaymakoglu S; Karaca C
    Clin Gastroenterol Hepatol; 2014 Oct; 12(10):1753-8. PubMed ID: 24582569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis.
    Gunsar F; Akarca US; Ersoz G; Kobak AC; Karasu Z; Yuce G; Ilter T; Batur Y
    Antivir Ther; 2005; 10(6):721-6. PubMed ID: 16218171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.
    Sagnelli E; Pisaturo M; Stanzione M; Messina V; Alessio L; Sagnelli C; Starace M; Pasquale G; Coppola N
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1174-1180.e11. PubMed ID: 23591280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.